Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

The FDA’s recent activities regarding Covid-19 vaccines stray far from the well-established standards of vaccine regulatory ...

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter ...

It began in 2020 with a coordinated push to generate public backlash to lockdowns. The ultimate aim was restoring normalcy, ending a politically and economically inconvenient crisis. Over time, ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

Novavax makes the nation’s only traditional protein-based coronavirus vaccine – and until now it had emergency authorization ...

This weekend, the FDA released its recommendation for Novavax, a vaccine designed to combat COVID-19. That in itself is not ...